PRKX inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the PRKX (protein kinase X) enzyme, a serine/threonine-specific kinase within the AGC kinase family. PRKX is known for its role in regulating various cellular processes, including cell proliferation, differentiation, and signal transduction pathways. Structurally, PRKX shares similarities with other protein kinases, particularly in its conserved ATP-binding domain and activation loop, which are critical regions for its catalytic function. The inhibitors in this class are designed to interfere with the ATP-binding site, effectively preventing PRKX from phosphorylating its target substrates. This interruption can influence downstream signaling pathways that are normally activated by PRKX, thereby modulating key biochemical processes within cells.
The specificity of PRKX inhibitors often relies on their precise molecular interactions with both the ATP-binding pocket and adjacent regulatory domains of the enzyme. Researchers designing these inhibitors aim for high selectivity, which requires a detailed understanding of the three-dimensional structure of PRKX. This has been aided by crystallographic studies and molecular docking simulations that reveal the key residues involved in inhibitor binding. The inhibition of PRKX is not merely a result of blocking its catalytic activity but can also involve allosteric modulation, where inhibitors bind to non-catalytic sites and induce conformational changes. These inhibitors are valuable tools in research for dissecting the exact role of PRKX in intracellular signaling pathways, allowing scientists to better understand how this kinase influences cellular behavior and function across different biological systems.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This DNA methyltransferase inhibitor could potentially lead to hypomethylation of the PRKX gene promoter, resulting in its suppressed transcription and consequent downregulation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, an HDAC inhibitor, may promote acetylation of histones associated with the PRKX gene, potentially decreasing its expression by altering chromatin structure and transcription factor access. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically targets mTOR signaling, which could result in the reduced translation of PRKX mRNA by affecting downstream targets involved in protein synthesis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
By specifically inhibiting PI3K, LY 294002 could lead to decreased activity of the Akt pathway, resulting in lowered transcriptional activation of the PRKX gene. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
This MEK inhibitor could lead to reduced activity of the ERK pathway, potentially resulting in decreased transcription factor activity and subsequent downregulation of PRKX. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 may lead to the specific inhibition of MEK1, consequently reducing ERK pathway signaling and leading to a decrease in PRKX gene expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
As a JNK inhibitor, SP600125 could specifically reduce AP-1 transcription factor activity, which may be involved in the transcriptional activation of PRKX, thereby decreasing its expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 targets p38 MAPK, possibly leading to the inhibition of downstream transcription factors that are crucial for PRKX expression, thereby reducing its levels. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, through its specific inhibition of PI3K, could decrease Akt pathway signaling and thus reduce the transcription and expression of PRKX. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin may exert its effects by downregulating NF-κB signaling, which could lead to the reduced expression of target genes including PRKX. | ||||||